Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apellis Pharmaceuticals, Inc.

http://www.apellis.com/

Latest From Apellis Pharmaceuticals, Inc.

Keeping Track: Gilead Gets CRL For Bulevirtide, CytoDyn Withdraws Leronlimab; Eye and CNS Drug Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

Apellis Aims New Pegcetacoplan Data At Market, Not Regulators

The company said the user fee goal date for pegcetacoplan in geographic atrophy would move from November to February as it submitted longer-term data.

FDA Ophthalmic

November Gloom? US FDA’s Goal Dates Include Hard Calls On Ferring Rebyota, Y-mAbs’ Omblastys

November should see FDA action on what could be the first standardized fecal microbiota transplant product, rare cancer therapies from Y-mAbs and Spectrum, uniQure/CSL’s hemophilia B gene therapy and Provention Bio’s biologic to delay type 1 diabetes.

US FDA Performance Tracker Drug Review

NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck

NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register